2 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Kevin Flanigan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. Amondys 45, Exondys 51, Vyondys 53 - Duchenne Muscular Dystrophy | Phase 2 | Completed | Kevin Flanigan | 3 | 2020-02-18 | 2023-10-26 |
| Spironolactone Versus Prednisolone in DMD Spironolactone, Prednisolone - Muscular Dystrophy, Duchenne | Phase 1 | Terminated | Kevin Flanigan | 2 | 2018-12-05 | 2023-10-23 |
| Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy rAAVrh74.MCK.GALGT2 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Kevin Flanigan | 2 | 2017-11-06 | 2025-03-13 |
| Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2 rAAVrh74.MCK.GALGT2, PLACEBO (Saline) - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Withdrawn | Kevin Flanigan | 2016-04-01 | 2018-02-06 |
Muscular Dystrophy, Duchenne (4)
Prednisolone (1) · Sodium Chloride (1) · Spironolactone (1) · casimersen (1) · eteplirsen (1) · golodirsen (1)
United States (4)